Preparation, characterization and systemic application of self-assembled hydroxyethyl starch nanoparticles-loaded flavonoid Morin for hyperuricemia therapy
Authors:
Open Access
- 1 April 2018
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 2129-2141
Abstract
Background: Morin, one of the most widely distributed flavonoids in plants, has been identified as a potent antihyperuricemic agent. Its poor water solubility and fast in vivo clearance, however, have limited its application in the treatment of hyperuricemia. In this study, a novel amphiphilic polymer (hydroxyethyl starch-deoxycholic acid [HES-DOCA]) was synthesized to overcome these limitations. Methods: HES-DOCA conjugates with various substitution degrees were prepared by chemical grafting DOCA to HES through ester formation. The structures of the conjugates were confirmed by infrared spectroscopy and 1H-NMR. Physicochemical characterizations of HES-DOCA nanoparticles-loaded Morin (Morin/HES-DOCA-NPs) were studied using dynamic light scattering and transmission electron microscopy (TEM). In vitro release studies were performed to evaluate the release properties of Morin from the NPs. Subsequently, in vivo pharmacokinetic parameters of Morin/HES-DOCA-NPs were investigated in Wistar rats through intravenous administration (2 mg/kg, equivalent to Morin). Antihyperuricemic efficacy of the NPs was evaluated in a rat hyperuricemic model. Results: The optimized HES-based amphiphilic polymer contained approximately 10 DOCA groups per 100 anhydroglucose units of HES, which can spontaneously self-assemble to form spherical NPs as demonstrated by TEM images. Morin/HES-DOCA-NPs were monodispersed (polydispersity index = 0.05) with a mean diameter of 197 nm and exhibited a zeta potential of -14 mV. The use of DOCA as the polymer’s hydrophobic segment enabled high drug loading efficiency (15.6%). After systemic administration, Morin/HES-DOCA-NPs exhibited significantly longer half-life and higher systemic exposure (elimination half-life and area under the plasma concentration–time curve) compared with free drug Morin. In a rat hyperuricemic model, treatment with Morin/HES-DOCA-NPs demonstrated superior therapeutic efficacy over Morin in decreasing serum uric acid level, increasing the uricosuric action, as well as attenuating hyperuricemia-associated inflammation in kidney of rats. Conclusion: Collectively, these findings suggest that the novel HES-based NP formulation of Morin may have great potential for clinical treatment of hyperuricemia.Keywords
This publication has 24 references indexed in Scilit:
- Morin: A Promising Natural DrugCurrent Medicinal Chemistry, 2016
- Mechanism of Enhanced Oral Absorption of Morin by Phospholipid Complex Based Self-Nanoemulsifying Drug Delivery SystemMolecular Pharmaceutics, 2015
- Physicochemical characterization of amphiphilic nanoparticles based on the novel starch–deoxycholic acid conjugates and self-aggregatesCarbohydrate Polymers, 2014
- Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactantsInternational Journal of Pharmaceutics, 2013
- Suppressing Unspecific Cell Uptake for Targeted Delivery Using Hydroxyethyl Starch NanocapsulesBiomacromolecules, 2012
- Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxelBiomaterials, 2012
- Self-assembled hyaluronic acid nanoparticles for active tumor targetingBiomaterials, 2010
- Update on gout: new therapeutic strategies and optionsNature Reviews Rheumatology, 2010
- Hydrophobically Modified Hydroxyethyl Starch: Synthesis, Characterization, and Aqueous Self-Assembly into Nano-Sized Polymeric Micelles and VesiclesBiomacromolecules, 2007
- The Dual Actions of Morin (3,5,7,2′,4′-Pentahydroxyflavone) as a Hypouricemic Agent: Uricosuric Effect and Xanthine Oxidase Inhibitory ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2006